Skip to content

Artiva Biotherapeutics, Inc.

ARTV

CIK 0001817241

← back to feed
Revenue (TTM)
$32.92M
Q1 Apr 2026
Net Income (TTM)
−$86.61M
−28.3% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.53
+41.0% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-280.4%
Q1 Apr 2026
Net Margin
-263.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$79.34M
Q1 Apr 2026
Cash
$20.96M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
24.72M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings